Physician profile
Robert A Ettlinger
NPI 1811983927
$19,085.52
in general payments reported to CMS, 2019-2025
54 companies · $3,060 in 2025
The $3,060 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,247 · 2020: $2,684 · 2021: $2,924 · 2022: $1,799 · 2023: $2,834 · 2024: $3,538 · 2025: $3,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,413 · Education: $19.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,412.69 |
| Education | $19.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,799.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,671.08 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Abbvie INC. | $1,600.16 | 2021-2025 | |
| Lilly USA, LLC | $1,474.86 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Pfizer INC. | $1,418.09 | 2019-2025 | |
| Novo Nordisk INC | $1,337.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $776.90 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $583.02 | 2021-2025 | |
| Dexcom, INC. | $546.59 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $485.94 | 2019-2022 | |
| Amgen INC. | $418.12 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $412.52 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $407.32 | 2019-2025 | Xifaxan |
| Aytu Biopharma, INC. | $400.00 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $386.00 | 2020-2025 | Rexulti |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $380.71 | 2019-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $363.58 | 2019-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $353.63 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $345.86 | 2019-2022 | |
| Exact Sciences Corporation | $330.58 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $234.11 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $220.99 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $178.00 | 2019-2023 | Xarelto |
| Lundbeck LLC | $161.11 | 2023-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $158.60 | 2022 | |
| Phathom Pharmaceuticals, INC. | $149.56 | 2024-2025 | Voquezna |
| Allergan, INC. | $142.86 | 2019-2020 | |
| Bridgebio Pharma, INC. | $122.50 | 2025 | Attruby |
| Sumitomo Pharma America, INC. | $102.15 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $102.02 | 2023-2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $98.50 | 2021-2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $92.86 | 2021-2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $90.21 | 2021 | |
| Mylan Specialty L.P. | $88.21 | 2021 | |
| Genentech USA, INC. | $84.39 | 2019-2021 | |
| Sanofi Pasteur INC. | $75.64 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.64 | 2020-2024 | Caplyta |
| Cequr Corporation | $48.73 | 2023-2024 | Cequr Simplicity |
| Axsome Therapeutics, INC. | $44.23 | 2024-2025 | Auvelity |
| Verona Pharma, INC. | $34.90 | 2025 | Ohtuvayre |
| Corium, LLC | $31.66 | 2025 | Azstarys |
| Daiichi Sankyo INC. | $31.49 | 2019-2020 | |
| Eisai INC. | $29.81 | 2021 | |
| Nestle Healthcare Nutrition INC. | $24.76 | 2021 | |
| Medtronic, INC. | $24.51 | 2025 | Minimed 780g |
| Abbott Laboratories | $22.95 | 2023 | Freestyle Libre |
| Sonex Health, INC. | $22.26 | 2025 | Sx-One Microknife |
| Circassia INC. | $20.74 | 2019 | |
| Corcept Therapeutics | $19.07 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $18.47 | 2020 | |
| Ironshore Pharmaceuticals INC. | $18.38 | 2019 | |
| Currax Pharmaceuticals LLC | $15.86 | 2025 | Contrave |
| Inspire Medical Systems, INC. | $15.49 | 2024 | Inspire |
| Bardy Diagnostics, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ettlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.